ArticleClinical drug investigation2003

Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model.

Claude Lepen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.